Strategic Partnerships

In June 2019, Nurix entered into a global strategic collaboration with Gilead to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.

Gilead Logo

In September 2015, Nurix entered an exclusive collaboration with Celgene for the discovery and development of next-generation therapies targeting E3 ubiquitin ligases in oncology, immunology and inflammation. The collaboration is focused on advancing novel therapies that directly manipulate E3 ligases to control protein levels. Celgene is a global leader in developing and commercializing therapies targeting the ubiquitin proteasome system.